Palbociclib Dimesylate Crystallization for Impurity A Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing processes for producing Palbociclib often result in the compound containing Impurity A, which is difficult to remove, leading to the need for robust and efficient methods to achieve high chemical purity and reduce impurity levels.

Innovation Solution

The development of solid state forms of Palbociclib dimesylate, specifically crystalline forms E, F, and G, which are characterized by specific XRPD patterns, FT-IR spectra, and 13C NMR spectra, utilizing methanesulfonic acid in the conversion process to significantly reduce Impurity A levels, thereby improving the purity and yield of Palbociclib.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If existing processes are used to produce Palbociclib, then production can be achieved, but Impurity A levels remain high and are difficult to remove

Engineering Contradiction:

Improvechemical purityVSAvoidImpurity A levels

Core Design Contradiction:

Manufacturing precisionVSObject-generated harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the crystallization conditions (temperature, solvent composition, pH) to obtain specific polymorphic forms of Palbociclib dimesylate that have different solubility and purity characteristics. This allows selective purification where Impurity A is excluded from the crystal lattice, achieving >99% purity with Impurity A levels below 0.1%.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent utilizes phase transitions through controlled crystallization processes where Palbociclib dimesylate transitions from solution to solid crystalline form. By controlling the phase transition conditions (cooling rate, solvent removal, seeding), the patent achieves selective incorporation of Palbociclib into crystals while excluding Impurity A, thereby purifying the product.

Inventive Principle:

Principle #36Phase transitions

2Manufacturing precision

If multiple purification steps are added to remove Impurity A, then chemical purity improves, but process complexity and time increase

Engineering Contradiction:

Improvechemical purityVSAvoidprocess complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent extracts Impurity A from the system by designing a crystallization process where Impurity A remains in the mother liquor while Palbociclib dimesylate crystallizes in pure form. This single extraction step through controlled crystallization replaces multiple purification operations, simplifying the process while achieving high purity.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent performs preliminary action by forming the dimesylate salt early in the synthesis process, which fundamentally changes the solubility and crystallization behavior of the compound. This preliminary salt formation enables subsequent easy purification through crystallization, avoiding the need for complex post-synthesis purification steps.

Inventive Principle:

Principle #10Preliminary action

3Productivity

If conventional crystallization methods are used, then Palbociclib can be obtained, but Impurity A contamination persists

Engineering Contradiction:

Improveproduction efficiencyVSAvoidpurity

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent uses methanesulfonic acid as an intermediary to form the dimesylate salt of Palbociclib. This intermediary compound has distinct crystallization properties that enable high-purity isolation. The dimesylate acts as a mediator that facilitates pure crystal formation while leaving Impurity A in solution, achieving both high productivity and high purity in a single step.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The described processes achieve Palbociclib with Impurity A levels below 0.1%, enabling high-quality production suitable for industrial scales and ensuring the solid state forms have enhanced chemical purity, stability, and handling characteristics.

Implementation Method 1

utilizing methanesulfonic acid in the conversion process to significantly reduce Impurity A levels, thereby improving the purity and yield of Palbociclib

Methodology Applied

Scientific EffectChemical reaction: Chemical Bonding